10-Q - Bright Green Corp (0001886799) (Filer)

8-K - Bright Green Corp (0001886799) (Filer)

NT 10-Q - Bright Green Corp (0001886799) (Filer)

DEF 14A - Bright Green Corp (0001886799) (Filer)

PRER14A - Bright Green Corp (0001886799) (Filer)

8-K - Bright Green Corp (0001886799) (Filer)

PRE 14A - Bright Green Corp (0001886799) (Filer)

144 - Bright Green Corp (0001886799) (Subject)

144 - Bright Green Corp (0001886799) (Subject)

144 - Bright Green Corp (0001886799) (Subject)

4 - Bright Green Corp (0001886799) (Issuer)

4 - Bright Green Corp (0001886799) (Issuer)

4/A - Bright Green Corp (0001886799) (Issuer)

4/A - Bright Green Corp (0001886799) (Issuer)

4 - Bright Green Corp (0001886799) (Issuer)

4/A - Bright Green Corp (0001886799) (Issuer)

4 - Bright Green Corp (0001886799) (Issuer)

4 - Bright Green Corp (0001886799) (Issuer)

4 - Bright Green Corp (0001886799) (Issuer)

4 - Bright Green Corp (0001886799) (Issuer)

GRANTS, NEW MEXICO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company"), today announced that trading of its shares have been suspended from the Nasdaq Stock Exchange ("Nasdaq") after Nasdaq cancelled the scheduled September 26, 2024 delist appeal hearing. While this development represents a change in the Company's public trading status, Bright Green remains committed to pursuing its strategic goals and delivering value to its shareholders. The Company filed its Proxy Statement and will proceed with its scheduled annual meeting on November 15, 2024, during which shareholders will discuss key issues, including the potential for a reve

GRANTS, NEW MEXICO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company") today announced that it has signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, as well as psychedelic molecules currently under investigation for clinical use. This completely homegrown agreement signals Bright Green's ability and commitment to supply US pharmaceutical partners with high quality organic materials. As part of the supply agreement proposed in the LOI, Benuvia intends to leverage Bright Gr

GRANTS, NEW MEXICO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company") today announced that it has signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, as well as psychedelic molecules currently under investigation for clinical use. This completely homegrown agreement signals Bright Green's ability and commitment to supply US pharmaceutical partners with high quality organic materials. As part of the supply agreement proposed in the LOI, Benuvia intends to leverage Bright Gree

GRANTS, NEW MEXICO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company") today announced that the Company has engaged an investment bank with vast experience to formally explore a $15.0 million debt financing to drive commercialization efforts forward on the first 20 acres of its recently U.S. Drug Enforcement Agency ("DEA") reinspected facility. In the interim, Bright Green has secured a $3.5 million capital commitment under its existing line of credit with Lynn Stockwell. As part of the capital commitment, the line of credit agreement has been amended to include security against the Company's greenhouse facility and a conversion opti

GRANTS, NEW MEXICO, May 30, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) Dear BGXX Shareholders, I'm writing to you today to share an update on several developments for Bright Green Corporation ("Bright Green" or the "Company") over the past few months. We've experienced massive shifts within the industry since the start of 2024 — shifts that have presented exciting growth opportunities for Bright Green. I'll begin with an update on the state of our groundbreaking EB-5 investment program in partnership with Asia Capital Pioneers Group ("ACPG"). I'm thrilled to share with you that we have confirmed our first t

GRANTS, NEW MEXICO, March 14, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company") Today announced that BGXX will install a 102-megawatt solar field to power the electricity and heating requirements for the new $250 million Dalsem expansion project and commits to switch the existing facility that currently burns natural gas and heavy oil to solar. This ensures that the BGXX production and drug manufacturing requirements in Grants, New Mexico are carbon neutral. The company started the bid process and is working with several Solar Installation Companies domiciled in New Mexico to install a 102-Megawatt Solar Power Generation field. The

GRANTS, NEW MEXICO, March 12, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company") today announced that it has signed an agreement with Dalsem Greenhouse Technologies BV for a $250 million construction project to expand the Company's current research, production and extraction processing facility located in rural Grants, New Mexico (the "Dalsem Agreement"). The proposed expansion will add 7 million square feet of manufacturing and production capabilities. The Dalsem Agreement provides that Dalsem will construct the additional facility to its specifications and build them in a modular fashion. Additionally, the Company has entered into a credit

The application follows the Company's approval from the New Mexico Board of Pharmacy this year. GRANTS, NM, March 07, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation, a Delaware corporation (the "Company"), announced today the submission of its DEA Registration for Bulk Production of Schedule I and Schedule II Controlled Substances. The application is an official and substantial step in Bright Green's expansion into the legal manufacturing of plant-based controlled substances including psilocybin, peyote, ibogaine, coca leaves, and opium poppy, alongside their active pharmaceutical ingredients ("API") for medical, research, and other legal purposes. The move aligns with Bright Green's c

BRIGHT GREEN CORPORATION BREAKS NEW GROUND IN DOMESTIC PHARMACEUTICAL PRODUCTION GRANTS, N.M., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company") company announced today that final approval has been received from the New Mexico Board of Pharmacy and the DEA for unique licensing that allows Bright Green to register, license, and authorize Schedule I and Schedule II plant-based drugs and Active Pharmaceutical Ingredients (APIs) for research, production, and manufacturing purposes. Schedule I Substances include Psilocybin, psilocybin, mescaline, peyote, ibogaine Schedule II Substances: Opium, poppy straw, raw opium, opium extracts, po

CEO, Groovy Singh appointed as a new member of the Company's Board Founder, Lynn Stockwell, appointed as Chair of the Board of Directors Grants, New Mexico, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) – Bright Green Corporation, a Delaware corporation (the "Company"), announced Friday that CEO Groovy Singh is the newest member of the company's Board of Directors (the "Board"). Current board member and Co-Founder Lynn Stockwell was also announced as the new Chair of the Board. Singh and Stockwell's appointments follow the resignation of the Executive Chairman, Terry Rafih. Mr. Rafih's resignation was not a result of any disagreement with the Company, the Boar

SC 13D/A - Bright Green Corp (0001886799) (Subject)

SC 13D - Bright Green Corp (0001886799) (Subject)

SC 13G/A - Bright Green Corp (0001886799) (Subject)

SC 13D - Bright Green Corp (0001886799) (Subject)

SC 13D - Bright Green Corp (0001886799) (Filed by)

Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Jan. 14, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently

Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently

Bright Green has achieved several key milestones throughout the Quarter significantly advancing progress against its strategic plan, including a historic DEA Federal Registration and License Approval. Commencement of its fundamental capital raise of $500+ million utilizing the U.S. Citizen & Immigration Services EB-5 program, alongside the recently announced full acquisition of Alterola Biotech, showcases the Company's significant progress against its strategic plan. Company has raised short-term working Capital of $5.26m to commence its operations as it looks to capitalize on its historic DEA Registration in Q2 2023 and beyond. GRANTS, N.M., May 24, 2023 (GLOBE NEWSWIRE) -- Brig

Continued investment to support long-term strategy and pathway for growth, including plans to fully acquire Alterola Biotech, appointment of Seamus McAuley as Chief Executive Officer and expansion of Scientific Advisory Board Recently announced capital raise plan of $500+ million utilizing the U.S. Citizen & Immigration Services EB-5 program, alongside the recently announced full acquisition of Alterola Biotech, showcases the Company's significant progress against its strategic plan Company preparing for federal registration from U.S. Drug Enforcement Administration as bulk cannabis manufacturer, which will position Bright Green to become the largest, fully integrated operation

Terry Rafih to remain as Executive Chairman of the Board Appointment reinforces Company's strategy to build out its team to deliver on the development of cannabis-based medicines and products, as well as its greenhouse expansion plans The Company confirms the receipt of its first funds from its EB-5 program GRANTS, N.M., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today announce

Bright Green reaches several key milestones, advancing progress against its strategic plan Company remains on track to start cultivation by the end of the year GRANTS, N.M., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), one of few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today reported financial results for the quarter ended September 30, 2022. "This quarter, Bright Green reached several key operational and strategic milestones validating our plan to bec

GRANTS, N.M., Oct. 11, 2022 (GLOBE NEWSWIRE) --  Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today announced that it has expanded its Scientific Advisory Board ("SAB"). The SAB – comprised of a strong group of industry leaders and chaired by Colin Stott, Chief Operating Officer at Alterola Biotech, Inc. (OTC:ABTI) – will work cohesively with Bright Green's senior management to advance the Company's long-term business growth and

https://patentcenter.uspto.gov/applications/18213409/ifw/docs

Gainers Avidity Biosciences (NASDAQ:RNA) shares rose 24.5% to $36.0 during Wednesday's pre-market session. The company's market cap stands at $3.4 billion. Molecular Partners (NASDAQ:MOLN) shares moved upwards by 18.43% to $5.91. The market value of their outstanding shares is at $196.1 million. Longeveron (NASDAQ:LGVN) shares increased by 15.84% to $0.95. The company's market cap stands at $6.0 million. TRACON Pharma (NASDAQ:TCON) shares increased by 15.74% to $1.25. The market value of their outstanding shares is at $3.3 million. Oramed Pharmaceuticals (NASDAQ:ORMP) stock moved upwards by 14.49% to $2.37. The market value of their outstanding shares is at $96.2 million. NovaBay Pharm

Shares of GameStop Corp. (NYSE:GME) fell sharply during Friday's session after the company released worse-than-expected first-quarter results before schedule and filed to sell up to 75 million shares. GameStop released its first-quarter 2024 results early Friday ahead of its scheduled June 11 date. The company reported net sales of $881.8 million, down from $1.237 billion year-over-year. The net sales total missed a consensus estimate of $995.3 million. The company reported a loss of 12 cents per share, missing the estimate of a loss of 9 cents per share, according to data from Benzinga Pro. GameStop shares dipped 22.5% to $36.07 on Friday. Here are some other stocks moving in today

Shares of Braze, Inc. (NASDAQ:BRZE) rose sharply in today's pre-market trading following better-than-expected first-quarter earnings. Braze reported first-quarter revenue of $135.459 million, beating estimates of $131.668 million. The company reported a first-quarter adjusted loss of 5 cents per share, beating estimates for a loss of 10 cents per share, according to Benzinga Pro. Braze shares jumped 14.3% to $42.02 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Venus Concept Inc. (NASDAQ:VERO) rose 135.8% to $1.46 in today's pre-market trading after gaining 16% on Thursday. Venus Concept was notified it regained compliance

Gainers Venus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. The market value of their outstanding shares is at $9.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares increased by 8.58% to $2.15. The market value of their outstanding shares is at $3.1 million. Applied DNA Sciences (NASDAQ:APDN) stock moved upwards by 8.27% to $0.59. The market value of their outstanding shares is at $6.0 million. Kiora Pharmaceuticals (NASDAQ:KPRX) shares rose 5.0% to $0.45. The market value of their outstanding shares is at $11.9 million. Fractyl Health (NASDAQ:GUTS) shares moved upwards by 4.94% to $6.79. The market value of their outstanding shares is at

Shares of Lands’ End, Inc. (NASDAQ:LE) fell sharply during Wednesday's session following first-quarter results. Lands’ End reported quarterly adjusted loss of 20 cents per share which beat the analyst consensus estimate of 26 cents per share. The company reported quarterly sales of $285.47 million which beat the analyst consensus estimate of $269.82 million, according to data from Benzinga Pro. Lands’ End shares dipped 9.3% to $12.60 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Actelis Networks, Inc. (NASDAQ:ASNS) shares jumped 512% to $2.88 after the company announced orders for cyber-hardened networking technology to be deployed at thr

Gainers ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 79.2% to $0.15 during Wednesday's regular session. The company's market cap stands at $1.6 million. Rezolute (NASDAQ:RZLT) stock moved upwards by 23.91% to $5.76. The company's market cap stands at $231.2 million. Bright Green (NASDAQ:BGXX) shares rose 23.07% to $0.36. The company's market cap stands at $69.0 million. Champions Oncology (NASDAQ:CSBR) shares increased by 22.42% to $5.65. The company's market cap stands at $76.8 million. Kineta (NASDAQ:KA) shares moved upwards by 22.11% to $0.53. The market value of their outstanding shares is at $6.4 million. CVRx (NASDAQ:CVRX) stock moved upwards by 21.57% to $7.89. The marke

Shares of Stitch Fix, Inc. (NASDAQ:SFIX) rose sharply in today's pre-market trading following better-than-expected third-quarter financial results. Stitch Fix reported quarterly losses of 18 cents per share which beat the analyst consensus estimate of losses of 24 cents by 25%. Quarterly sales came in at $322.7 million which beat the analyst consensus estimate of $306.121 million by 5.42% and represents a 18.29% decrease in sales from the same period last year, according to data from Benzinga Pro. Stitch Fix shares jumped 18% to $3.15 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Actelis Networks, Inc. (NASDAQ:ASNS) rose 7

Gainers FibroGen (NASDAQ:FGEN) stock moved upwards by 24.4% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $152.1 million. Candel Therapeutics (NASDAQ:CADL) stock increased by 8.12% to $9.05. The company's market cap stands at $269.2 million. RAPT Therapeutics (NASDAQ:RAPT) shares moved upwards by 7.53% to $4.28. The market value of their outstanding shares is at $149.3 million. Gritstone Bio (NASDAQ:GRTS) shares increased by 7.24% to $0.79. The market value of their outstanding shares is at $85.4 million. Scholar Rock Holding (NASDAQ:SRRK) shares rose 6.96% to $10.14. The company's market cap stands at $808.7 million. Novo Integrated

Gainers Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 70.4% to $3.51 during Monday's pre-market session. The market value of their outstanding shares is at $5.8 million. Molecular Partners (NASDAQ:MOLN) shares moved upwards by 21.72% to $4.38. The company's market cap stands at $144.0 million. Structure Therapeutics (NASDAQ:GPCR) shares moved upwards by 19.23% to $40.78. The company's market cap stands at $1.9 billion. NewGenIvf Group (NASDAQ:NIVF) stock rose 16.78% to $1.6. The company's market cap stands at $16.2 million. Kyverna Therapeutics (NASDAQ:KYTX) shares increased by 16.6% to $14.61. The market value of their outstanding shares is at $629.9 million. ARCA biopharma (NAS